By Ana Espino | Published on August 14, 2025 | 2 min read#Schizophrenia #CognitiveFunction
#MetabolicDisorder
Schizophrenia is a
severe
psychiatric disorder characterized by psychotic symptoms, cognitive
impairments, and global disruption of social and occupational functioning.
Among its many associated comorbidities,
metabolic disorders—particularly
impaired glucose regulation—play a central role. These abnormalities, often
present from the earliest stages of the illness, are linked both to the effects
of antipsychotic treatment and to pathophysiological factors inherent to
schizophrenia.
Current treatments mainly
target
psychotic symptoms, but their
impact on metabolic disturbances and cognitive
functions remains limited. Cognitive deficits are among the main determinants
of functional disability and may be exacerbated by abnormalities in glucose
homeostasis. A major challenge is therefore to better understand the
relationship between glucose regulation and cognitive performance in
schizophrenia, in order to identify potential therapeutic targets and improve
overall patient care.
In this context, this study set out
to evaluate the association between metabolic parameters (blood glucose,
insulin, HOMA-IR) and cognitive performance across different domains in
patients with schizophrenia.
What if blood sugar dictated our
thoughts?
A total of
175 patients diagnosed
with
schizophrenia were assessed both
metabolically and
cognitively. Metabolic
measures included
fasting blood glucose, fasting insulin, and the
HOMA-IR
(
Homeostasis Model Assessment of Insulin Resistance)
index. Cognitive functions
were evaluated using a
standardized battery covering
verbal and
visual memory,
attention, processing speed, executive function, and
motor skills.
Analyses revealed that
higher
fasting glucose and insulin levels, as well as a
higher HOMA-IR, were
significantly
associated with poorer performance in several cognitive domains,
particularly verbal memory, sustained attention, and processing speed. These
associations persisted after adjusting for age, sex, BMI, illness duration, and
antipsychotic treatment. The findings suggest a
potential role of insulin
resistance in
cognitive decline, independent of other clinical factors.
Caring for metabolism to protect the
mind
Schizophrenia is a severe
psychiatric disorder which, beyond its psychotic manifestations, is frequently
accompanied by
metabolic disturbances that can
impair cognitive functions. The
main challenge lies in jointly addressing psychiatric and metabolic dimensions
to preserve patients’ overall functioning.
The aim of this study was to
explore
the link between glucose homeostasis and
cognitive performance, in order to
identify new avenues for integrated care. The results highlight a
significant
association between impaired glucose regulation and cognitive deficits—especially
in
verbal memory and attention—suggesting that
early metabolic monitoring could
help preserve cognitive abilities and improve functional prognosis.
Longitudinal studies will be needed
to confirm these findings and support the systematic integration of metabolic
follow-up in psychiatric care. They may also pave the way for the development
of integrated therapeutic strategies combining antipsychotic treatment with
targeted metabolic interventions, with the goal of optimizing both mental
health and metabolic profiles in patients.
Read next: Can loneliness be read on the face?
About the author – Ana EspinoPhD in Immunology, specialized in Virology
As a scientific writer, Ana is passionate about bridging the gap between research and real-world impact. With expertise in immunology, virology, oncology, and clinical studies, she makes complex science clear and accessible. Her mission: to accelerate knowledge sharing and empower evidence-based decisions through impactful communication.